Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment

Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, et al. Hepatology. 2017;66(2):389-397.

Publication Type:

Journal Article

Authors:

Poordad, Fred; Felizarta, Franco; Asatryan, Armen; et, al

Source:

Hepatology, Volume 66, Issue 2, p.389-397 (2017)

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/28128852

Export Citation:

RIS Format

Top